FAIRMOUNT FUNDS MANAGEMENT LLC
Q2 2024 Form 13-F

WEST CONSHOHOCKEN, PENNSYLVANIA
CIK 0001802528 · CRD 284844 · SEC-registered investment adviser
$885.1M Reported Value Total

FAIRMOUNT FUNDS MANAGEMENT LLC reports 4 total accounts under management (AUM). There are 4 discretionary accounts valued at $2,276,508,000, and 0 non-discretionary accounts.

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered Discretionary Manager
Private funds (Form ADV)
12 funds · $6.1B gross asset value
Hedge Fund: $5.7B · Private Equity Fund: $342.0M
Source: Form ADV filed 2026-08-07
Reported value
$885.1M
Quarter over quarter
-8.1%
Holdings
13
Top-10 concentration
94.3%

Key People

Form ADV owners & control persons
Peter Evan Harwin
MANAGING MEMBER
Tomas Kiselak
MANAGING MEMBER
Emily Florence Curtiss
GENERAL COUNSEL

Filing Navigation

13F Metrics

Loading 13F Metrics

Q2 2024 13F record

Q2 2024 13F filing summary

Q2 2024 Form 13F portfolio summary
Period of report June 30, 2024
Filed August 14, 2024
Form 13F-HR
Reported value $885.1M
Positions 13
Change in reported value -3.5%
New positions 2
Exited positions 4
Position turnover 35.3%
Top-10 concentration 94.3%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 16, 2026
12 $1.6B
Q2 2026 13F
Filed Aug 14, 2026
12 $1.5B
Q1 2026 13F
Filed May 15, 2026
12 $1.4B
Q4 2025 13F
Filed Feb 17, 2026
13 $1.3B
Q3 2025 13F
Filed Nov 14, 2025
17 $1.1B
Q2 2025 13F
Filed Aug 14, 2025
17 $771.9M
Q1 2025 13F
Filed May 15, 2025
15 $644.6M
Q4 2024 13F
Filed Feb 14, 2025
17 $1.0B
Q3 2024 13F
Filed Nov 14, 2024
15 $1.2B
Q2 2024 13F
Filed Aug 14, 2024
13 $885.1M
Q1 2024 13F
Filed May 15, 2024
15 $917.4M
Q4 2023 13F
Filed Feb 14, 2024
16 $946.5M
Q3 2023 13F
Filed Nov 14, 2023
20 $831.2M
Q2 2023 13F
Filed Aug 14, 2023
17 $709.3M
Q1 2023 13F
Filed May 15, 2023
16 $581.5M
Q4 2022 13F
Filed Feb 14, 2023
16 $630.4M
Q3 2022 13F
Filed Nov 9, 2022
26 $568.9M
Q2 2022 13F
Filed Aug 15, 2022
27 $436.9M
Q1 2022 13F
Filed May 16, 2022
22 $422.9M
Q4 2021 13F
Filed Feb 14, 2022
20 $303.3M

8 earlier quarters on file — choose one from the quarter menu above.

Top 13 holdings · Q2 2024

Largest Q2 2024 13F positions by reported value
# Holding Reported value % of portfolio
1 AXSM AXSOME THERAPEUTICS INC $190.0M 21.46%
2 NUVL NUVALENT INC $146.0M 16.5%
3 SYRE SPYRE THERAPEUTICS INC $94.5M 10.67%
4 APGE APOGEE THERAPEUTICS INC $80.6M 9.11%
5 ELVN ENLIVEN THERAPEUTICS INC $74.8M 8.46%
6 DNTH DIANTHUS THERAPEUTICS INC $71.5M 8.08%
7 KNSA KINIKSA PHARMACEUTICALS INTL $59.8M 6.76%
8 COGT COGENT BIOSCIENCES INC $52.5M 5.93%
9 ATXS ASTRIA THERAPEUTICS INC $32.3M 3.65%
10 PTGX PROTAGONIST THERAPEUTICS INC $32.3M 3.65%
11 VRDN VIRIDIAN THERAPEUTICS INC $24.0M 2.71%
12 BCYC BICYCLE THERAPEUTICS PLC $21.6M 2.44%
13 TERN TERNS PHARMACEUTICALS INC $5.1M 0.58%

Values as reported on the Q2 2024 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings